CN110801444A - Transdermal absorption patch for treating onychomycosis and preparation method thereof - Google Patents

Transdermal absorption patch for treating onychomycosis and preparation method thereof Download PDF

Info

Publication number
CN110801444A
CN110801444A CN201810887188.4A CN201810887188A CN110801444A CN 110801444 A CN110801444 A CN 110801444A CN 201810887188 A CN201810887188 A CN 201810887188A CN 110801444 A CN110801444 A CN 110801444A
Authority
CN
China
Prior art keywords
polymer layer
layer
patch
treating
treating onychomycosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810887188.4A
Other languages
Chinese (zh)
Inventor
杨润田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810887188.4A priority Critical patent/CN110801444A/en
Publication of CN110801444A publication Critical patent/CN110801444A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a transdermal absorption patch for treating onychomycosis, which consists of a back lining layer, an adhesive polymer layer and a protective film layer, wherein the adhesive polymer layer comprises a medicament for treating the onychomycosis, an adhesive polymer and a penetration enhancer, and the medicament is ciclopirox olamine. The penetration enhancer is laurocapram or a traditional Chinese medicine mixture containing laurocapram. The invention also provides a preparation method of the patch. The patch can effectively promote ciclopirox olamine to permeate skin, and has the effect of treating onychomycosis. The skin administration can also avoid gastrointestinal enzymolysis and liver first-pass effect, reduce toxic and side effects, and reduce individual difference of administration. Meanwhile, ciclopirox olamine in the invention can be released at a stable rate, the drug effect can be stably maintained for about 3 days, and the administration frequency can be reduced. In addition, the invention has the advantages of simple and easily obtained raw materials, low cost, convenient patch tearing and application, convenient use, capability of avoiding polluting clothes and causing medicine loss, and strong practicability.

Description

Transdermal absorption patch for treating onychomycosis and preparation method thereof
Technical Field
The invention relates to a transdermal drug delivery patch, in particular to a transdermal absorption patch for treating onychomycosis, and also relates to a preparation method of the transdermal absorption patch for treating onychomycosis.
Background
Onychomycosis is an infectious disease that occurs on human nails and is medically known as onychomycosis, which is caused by fungal infection. Onychomycosis lesions begin at the distal end, lateral margins or folds of the nail and appear as abnormal nail color and morphology. The diseased nail plate is mostly grey white and loses luster, and the nail plate becomes brittle and is broken and falls off.
① the existing method for treating onychomycosis comprises scraping crisp diseased nails with a knife, or thinning the diseased nails, and then coating iodine tincture or glacial acetic acid solution.
② nail removal by operation, although the method is simple, the diseased nail is difficult to be completely removed and easy to recur, the severe pain caused by the operation and the possible secondary infection bring much inconvenience to life and work, and the method is rarely adopted at present.
③ oral antifungal medicines including griseofulvin, ketoconazole, etc. have unstable curative effect, small antibacterial range, high recurrence rate and side effect, and the medicine is needed for half a year to half a year, so it is used less.
④ broad-spectrum antibacterial ointment such as dacron cream, ketoconazole cream, bifonazole cream, ciclopirox olamine ointment, and compound preparation is applied externally, but the method is not easy to control the dosage, the administration frequency is frequent, and the method is easy to pollute clothes and cause medicine loss.
Disclosure of Invention
The invention aims to provide a transdermal absorption patch which has good curative effect, can continuously and stably administer the drug, reduces the administration times, can avoid gastrointestinal tract enzymolysis and liver first-pass effect, reduces the toxic and side effects of the drug, and is convenient to use for treating onychomycosis.
The invention adopts the following technical scheme: a percutaneous absorption paster for treating onychomycosis, which consists of a back lining layer, an adhesive polymer layer and a protective film layer, wherein the adhesive polymer layer comprises a medicament for treating the onychomycosis, an adhesive polymer and a penetration enhancer, and is characterized in that: the medicine for treating onychomycosis is ciclopirox olamine; the penetration enhancer is a traditional Chinese medicine mixture containing laurocapram and eucalyptus oil.
The traditional Chinese medicine mixture comprises laurocapram accounting for 1-10% of the weight of the viscous polymer layer, and eucalyptus oil accounting for 1-10% of the weight of the viscous polymer layer.
The traditional Chinese medicine mixture comprises laurocapram accounting for 1-10% of the weight of the viscous polymer layer, eucalyptus oil accounting for 1-10% of the weight of the viscous polymer layer, and one or more of terpene, saturated or unsaturated fatty acid and ester thereof, alcohol, silicone, sulfoxide, amide, lactam, phenol or pyrrolidone accounting for 1-50% of the weight of the viscous polymer layer. Among them, terpenes are, for example: menthol; saturated or unsaturated fatty acids and esters thereof, for example: capric acid, myristic acid, oleic acid, lauric acid, stearoyl sarcosine, diethylene glycol distearate, diethylene glycol dilaurate, diethylene glycol monocinnamate, diethylene glycol monolaurate, diethylene glycol monostearate, triglycerol monostearate, hexaglycerol monostearate, decaglycerol octaoleate, decaglycerol decaoleate, isopropyl myristate, isopropyl palmitate, ethyl oleate, ethyl lactate. Alcohols are, for example: ethanol, propylene glycol, oleyl alcohol, lauryl alcohol, cetyl alcohol, polyethylene glycol, terpineol; silicones such as: dimethyl silicone oil; sulfoxides such as: dimethyl sulfoxide, dodecyl methyl sulfoxide; amides such as: n, N-dimethylformamide, N-dimethylacetamide; lactams such as: dodecyl nitrone, farnesyl nitrone; phenols such as: thymol; pyrrolidones such as 1-methyl-2-pyrrolidone.
The ciclopirox olamine accounts for 1 to 15 percent of the weight of the viscous polymer layer; the adhesive polymer accounts for 20-80% of the weight of the adhesive polymer layer.
The viscous polymer is polyacrylate pressure-sensitive adhesive.
The back lining layer is an impermeable film made of one selected from high-density polyethylene, low-density polyethylene, polypropylene, polyvinyl chloride, ethylene-vinyl acetate copolymer, polyester, polyvinylpyrrolidone, polyvinyl alcohol, polymethyl carbamate and metal aluminum foil, or a composite film made of the metal aluminum foil and the polymer.
The back lining layer is one of a polyethylene-aluminum-polyethylene composite film, a low-density polyethylene film or a polyurethane film which is made of a low-density polyethylene film and a metal aluminum foil.
The surface of the viscous polymer layer is also provided with an adhesive layer; the adhesive layer is made of polyacrylate pressure-sensitive adhesive.
It is another object of the present invention to provide a method for preparing the above patch.
A method for preparing the transdermal absorption patch for treating the onychomycosis is characterized by comprising the following steps: uniformly mixing the adhesive polymer, ciclopirox olamine, the transdermal enhancer and the solvent, coating the mixture on a protective film layer to obtain an adhesive polymer layer, drying, cooling, covering a back lining layer on the other side of the adhesive polymer layer, and shearing into required sizes to obtain the transdermal absorption patch for treating the onychomycosis.
The transdermal absorption patch for treating onychomycosis contains ciclopirox olamine 1-14 mg per square centimeter.
The adhesive polymer layer comprises an adhesive polymer, the drug ciclopirox olamine and a penetration enhancer, which has both the functions of drug reservoir and adhesion. The viscous polymer layer is prepared by taking polyacrylate pressure-sensitive adhesive as a controlled-release framework material, dissolving a certain amount of ciclopirox olamine in laurocapram and a eucalyptus oil penetration enhancer or a mixed penetration enhancer containing laurocapram and eucalyptus oil, and uniformly distributing the ciclopirox olamine in the framework in the form of liquid micro-libraries by a solvent volatilization method. The release rate of ciclopirox olamine in the patch is adjusted by changing the drug content, the density of the liquid micro-reservoir and the proportion of the transdermal enhancer in the polymer.
The drug transdermal patch for treating onychomycosis, which is prepared from the laurocapram (namely 1-dodecyl azacycloheptane-2-one) transdermal enhancer or the traditional Chinese medicine mixture containing the laurocapram, can effectively promote ciclopirox olamine to permeate skin and has the effect of treating onychomycosis. The skin administration can also avoid gastrointestinal enzymolysis and liver first-pass effect, reduce toxic and side effects, and reduce individual difference of administration. Meanwhile, ciclopirox olamine in the invention can be released at a stable rate, so that the drug effect can be stably maintained for about 3 days, and the administration times are reduced by preparing the patch for a plurality of days. In addition, the invention has the advantages of simple and easily obtained raw materials, low cost, convenient patch tearing and application, convenient use and strong practicability, and can also avoid polluting clothes to cause loss of medicines.
Detailed Description
The invention is further illustrated by the following specific examples:
example 1
185g of viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 5g of ciclopirox olamine, 9g of transdermal enhancer laurocapram, 6g of eucalyptus oil, 65g of propylene glycol and 100g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, covering the other side of the adhesive polymer layer with a polyethylene-aluminum-polyethylene composite film backing layer, cutting into 5cm2 size patches, and allowing the patches per square centimeter to contain ciclopirox olamine 5mg, to obtain the transdermal absorption patch 1 for treating onychomycosis, wherein the adhesive polymer layer contains polyacrylate pressure-sensitive adhesive 46%, ciclopirox olamine 3%, laurocapram 6%, eucalyptus oil 4%, and propylene glycol 41%.
Example 2
225g of adhesive polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 14g of ciclopirox olamine, 9g of transdermal enhancer laurocapram, 3g of eucalyptus oil, 52g of ethanol and 125g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, cooling, covering the other side of the adhesive polymer layer with low-density polyethylene film backing layer, cutting into 5cm2 size patch, and allowing ciclopirox olamine to be contained in each square centimeter patch at a content of 14mg, to obtain the transdermal absorption patch 2 for treating onychomycosis, wherein the adhesive polymer layer contains polyacrylate pressure sensitive adhesive 54%, ciclopirox olamine 8%, laurocapram 5%, eucalyptus oil 3%, and ethanol 30%.
Example 3
300g of viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 9g of ciclopirox olamine, 6g of penetration enhancer laurocapram, 9g of eucalyptus oil, 40g of mixture of dimethyl silicone oil and oleyl alcohol and 134g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is vibrated on a vibrator for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, covering another side of the adhesive polymer layer with high-density polyethylene film backing layer, and cutting into 5cm2 size patches to make each square centimeter patch contain ciclopirox olamine 9mg, to obtain the transdermal absorption patch 3 for treating onychomycosis, wherein the adhesive polymer layer contains polyacrylate pressure-sensitive adhesive 65%, ciclopirox olamine 5%, laurocapram 3%, eucalyptus oil 5%, and dimethicone and oleyl alcohol mixture 22%.
Example 4
215g of viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 10g of ciclopirox olamine, 5g of transdermal enhancer laurocapram, 9g of eucalyptus oil, 10g of lauric acid, stearoyl sarcosine, a mixture of lauryl alcohol and dimethyl sulfoxide and 120g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept stand until bubbles disappear. Coating the mixture on a release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, covering the other side of the adhesive polymer layer with a polypropylene film backing layer, and cutting into 5cm2 size patches to make each square centimeter patch contain 10mg of ciclopirox olamine to obtain the transdermal absorption patch 4 for treating onychomycosis, wherein the adhesive polymer layer contains 73% of polyacrylate pressure-sensitive adhesive, 8% of ciclopirox olamine, 4% of laurocapram, 7% of eucalyptus oil, and 8% of a mixture of lauric acid, stearoyl sarcosine, lauryl alcohol and dimethyl sulfoxide.
Example 5
176g of a viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid content accounts for 40 percent), 7g of ciclopirox olamine, 9g of a penetration enhancer, 10g of eucalyptus oil, 6g of a mixture of cetyl alcohol and N, N-dimethylformamide and 135g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on a release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, covering the other side of the adhesive polymer layer with a back lining layer of polyurethane film, and cutting into pieces of 10cm2 size, wherein each square centimeter of pieces contains ciclopirox olamine 10mg, to obtain the transdermal absorption patch 5 for treating onychomycosis, wherein the adhesive polymer layer contains polyacrylate pressure-sensitive adhesive 69%, ciclopirox olamine 7%, laurocapram 9%, eucalyptus oil 9%, cetyl alcohol and N, N-dimethylformamide mixture 6%.
Example 6
200g of viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 9g of ciclopirox olamine, 10g of transdermal enhancer laurocapram, 1g of eucalyptus oil and 147g of solvent ethyl acetate are put into a wide-mouth bottle together, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on release paper, drying at 40 deg.C for 4 min, at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, covering another side of the adhesive polymer layer with polyvinyl chloride film backing layer, and cutting into pieces of 10cm2 size, wherein each square centimeter of pieces contains ciclopirox olamine 10mg, to obtain the transdermal absorption patch 6 for treating onychomycosis, wherein the adhesive polymer layer contains polyacrylate pressure-sensitive adhesive 80%, ciclopirox olamine 9%, laurocapram 10%, and eucalyptus oil 1%.
Example 7
100g of a viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 10g of ciclopirox olamine, 2g of a penetration enhancer, 8g of eucalyptus oil, 100g of terpineol and 160g of a solvent ethyl acetate are put into a wide-mouth bottle together, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is vibrated on a vibrator for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the above mixture on release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, covering the other side of the adhesive polymer layer with ethylene-vinyl acetate copolymer film backing layer, and cutting into pieces of size 10cm2 to make each square centimeter containing 8mg of ciclopirox olamine to obtain the transdermal absorption patch 7 for treating onychomycosis, wherein the adhesive polymer layer contains polyacrylate pressure-sensitive adhesive 40%, ciclopirox olamine 5%, laurocapram 1%, eucalyptus oil 4%, and terpineol 50%.
Example 8
50g of adhesive polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 10g of ciclopirox olamine, 10g of transdermal enhancer laurocapram, 10g of eucalyptus oil, 50g of a mixture of diethylene glycol monocinnamate, thymol and dodecyl azone and 100g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, coating a polyacrylate pressure-sensitive adhesive layer on the other side of the adhesive polymer layer, covering with a polyvinylpyrrolidone film backing layer, and cutting into 5cm 2-sized patches to contain 8mg of ciclopirox olamine per square centimeter of patch, to obtain the transdermal absorption patch 8 for treating onychomycosis, wherein the adhesive polymer layer contains 20% of polyacrylate pressure-sensitive adhesive, 10% of ciclopirox, 10% of laurocapram, 10% of eucalyptus oil, and 50% of a mixture of diethylene glycol mono cinnamate, thymol and dodecyl azone.
Example 9
198g of a viscous polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 1g of ciclopirox olamine, 5g of a penetration enhancer, 5g of laurocapram, 10g of a mixture of eucalyptus oil, oleic acid and ethyl oleate and 150g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is vibrated on a vibrator for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on release paper, drying at 40 deg.C for 4 min, drying at 60 deg.C for 2 min, drying at 90 deg.C for 2 min, cooling, coating a polyacrylate pressure-sensitive adhesive layer on the other side of the adhesive polymer layer, covering with a polyvinyl alcohol film backing layer, and cutting into 5cm 2-sized patches to contain ciclopirox olamine per square centimeter, to obtain the transdermal absorption patch 9 for treating onychomycosis, wherein the adhesive polymer layer contains 79% of polyacrylate pressure-sensitive adhesive, 1% of ciclopirox olamine, 5% of laurocapram, 5% of eucalyptus oil, and 10% of a mixture of oleic acid and ethyl oleate.
Example 10
60g of adhesive polymer polyacrylate pressure-sensitive adhesive (namely PSA, wherein the solid accounts for 40 percent), 15g of ciclopirox olamine, 1g of transdermal enhancer laurocapram, 10g of eucalyptus oil, 50g of mixture of diethylene glycol monolaurate and diethylene glycol dilaurate and 120g of solvent ethyl acetate are put into a wide-mouth bottle, the mouth of the wide-mouth bottle is sealed, the wide-mouth bottle is shaken on a shaker for 15 hours, and then the wide-mouth bottle is kept still until bubbles disappear. Coating the mixture on a release paper, drying at 40 ℃ for 4 minutes, drying at 60 ℃ for 2 minutes, drying at 90 ℃ for 2 minutes, cooling, coating a polyacrylate pressure-sensitive adhesive layer on the other side of the adhesive polymer layer, covering a metal aluminum foil film backing layer, and cutting into 5cm 2-sized patches to make each square centimeter of patch contain 14mg of ciclopirox olamine to obtain the transdermal absorption patch 10 for treating onychomycosis, wherein the adhesive polymer layer contains 24% of polyacrylate pressure-sensitive adhesive, 15% of ciclopirox olamine, 1% of laurocapram, 10% of eucalyptus oil and 50% of a mixture of diethylene glycol monolaurate and diethylene glycol dilaurate.

Claims (10)

1. A percutaneous absorption paster for treating onychomycosis, which consists of a back lining layer, an adhesive polymer layer and a protective film layer, wherein the adhesive polymer layer comprises a medicament for treating the onychomycosis, an adhesive polymer and a penetration enhancer, and is characterized in that: the medicine for treating onychomycosis is ciclopirox olamine; the penetration enhancer is a traditional Chinese medicine mixture containing laurocapram and eucalyptus oil.
2. The transdermal patch for treating onychomycosis according to claim 1, wherein: the traditional Chinese medicine mixture comprises laurocapram accounting for 1-10% of the weight of the viscous polymer layer, and eucalyptus oil accounting for 1-10% of the weight of the viscous polymer layer.
3. The transdermal patch for treating onychomycosis according to claim 1, wherein: the traditional Chinese medicine mixture comprises laurocapram accounting for 1-10% of the weight of the viscous polymer layer, eucalyptus oil accounting for 1-10% of the weight of the viscous polymer layer, and one or more of terpene, saturated or unsaturated fatty acid and ester thereof, alcohol, silicone, sulfoxide, amide, lactam, phenol or pyrrolidone accounting for 1-50% of the weight of the viscous polymer layer.
4. The transdermal patch for treating onychomycosis according to claim 1, wherein: the ciclopirox olamine accounts for 1 to 15 percent of the weight of the viscous polymer layer; the adhesive polymer accounts for 20-80% of the weight of the adhesive polymer layer.
5. The transdermal patch for treating onychomycosis according to claim 1, wherein: the viscous polymer is polyacrylate pressure-sensitive adhesive.
6. The transdermal patch for treating onychomycosis according to claim 1, wherein: the back lining layer is an impermeable film made of one selected from high-density polyethylene, low-density polyethylene, polypropylene, polyvinyl chloride, ethylene-vinyl acetate copolymer, polyester, polyvinylpyrrolidone, polyvinyl alcohol, polymethyl carbamate and metal aluminum foil, or a composite film made of the metal aluminum foil and the polymer.
7. The transdermal patch for treating onychomycosis according to claim 1, wherein: the back lining layer is one of a polyethylene-aluminum-polyethylene composite film, a low-density polyethylene film or a polyurethane film which is made of a low-density polyethylene film and a metal aluminum foil.
8. The transdermal patch for treating onychomycosis according to claim 1, wherein: the surface of the viscous polymer layer is also provided with an adhesive layer; the adhesive layer is made of polyacrylate pressure-sensitive adhesive.
9. A method of preparing the transdermal patch for treating onychomycosis according to claim 1, comprising: uniformly mixing the adhesive polymer, ciclopirox olamine, the transdermal enhancer and the solvent, coating the mixture on a protective film layer to obtain an adhesive polymer layer, drying, cooling, covering a back lining layer on the other side of the adhesive polymer layer, and shearing into required sizes to obtain the transdermal absorption patch for treating the onychomycosis.
10. The method for preparing a transdermal patch for treating onychomycosis according to claim 9, wherein: the transdermal absorption patch for treating onychomycosis contains ciclopirox olamine 1-14 mg per square centimeter.
CN201810887188.4A 2018-08-06 2018-08-06 Transdermal absorption patch for treating onychomycosis and preparation method thereof Pending CN110801444A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810887188.4A CN110801444A (en) 2018-08-06 2018-08-06 Transdermal absorption patch for treating onychomycosis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810887188.4A CN110801444A (en) 2018-08-06 2018-08-06 Transdermal absorption patch for treating onychomycosis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN110801444A true CN110801444A (en) 2020-02-18

Family

ID=69487319

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810887188.4A Pending CN110801444A (en) 2018-08-06 2018-08-06 Transdermal absorption patch for treating onychomycosis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN110801444A (en)

Similar Documents

Publication Publication Date Title
AU652121B2 (en) Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
KR930001082B1 (en) Device for administering an active agent to the skin or mucosa
US5683711A (en) Active ingredient patch
US5023084A (en) Transdermal estrogen/progestin dosage unit, system and process
US5560922A (en) Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US9700552B2 (en) Pharmaceutical compositions for treatment of addiction
US8883197B2 (en) Transdermal, therapeutic system with activatable oversaturation and controlled permeation promotion
GB2273044A (en) Medicinal patches for percutaneous administration
HUT74876A (en) Sexual steroid-containing transdermal therapeutic systems
US20060088580A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion
CN105287361A (en) External preparation containing non-steroid anti-inflammatory drug microemulsion and used for skin
US20030082227A1 (en) Transdermal device comprising a reservoir and a matrix containing the same active principle
AU2021260149A1 (en) Oral delivery system comprising hydroxychloroquine and/or chloroquine
HUT77383A (en) Plaster comprising scopolamine
US4788064A (en) Transdermal delivery system
EP3533443B1 (en) Percutaneous absorption formulation for treating sleep disorders
US7018648B2 (en) Transdermal device for administering testosterone or one of the derivatives thereof
KR20000000640A (en) Composition for percutaneous absorbing medication of non-steroidal aniphlogistic analgestic and making for percutaneous absorbing medication including composition
US20050232983A1 (en) Transdermal patch
CN1913878B (en) Transdermal delivery of hormones without the need of penetration enhancers
CN110801444A (en) Transdermal absorption patch for treating onychomycosis and preparation method thereof
WO2012069820A1 (en) Multi-layered transdermal patch
US20180360769A1 (en) Systems and methods for transdermal drug delivery
AU2021256454A1 (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
WO1993024114A1 (en) Reservoir-type plaster containing ketorolac

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200218

WD01 Invention patent application deemed withdrawn after publication